Incretin mimetics carry very low hypoglycaemia risk when used alone because they only stimulate insulin when blood glucose is elevated
The clinic aims at metabolic health and provides a medically directed program that is established on the basis of lab work, body composition analysis, and in-clinic support
India, where Novo Nordisk's patent was rejected, will likely see generic semaglutide by late 2026
Dose escalation should proceed slowly if dizziness emerges
Costs are divided into initial intensive sessions and ongoing maintenance treatments, with packages often offering better value
With a focus on rigorous medical monitoring, including regular blood work, personalized care helps mitigate risks associated with improper use